Pfizer moves global clindamycin manufacture to China with Hisoar
This article was originally published in Scrip
Executive Summary
The major Chinese active pharmaceutical ingredients (API) manufacturer Zhejiang Hisoar is aggressively upgrading its capabilities in a move designed to serve a broader range of clients. The firm has signed a 20-year agreement with Pfizer Asia Manufacturing, the Singapore-based API sourcing and manufacturing arm of Pfizer, related to clindamycin, one of its main products.